<DOC>
	<DOCNO>NCT02542696</DOCNO>
	<brief_summary>A 24-week , prospective , multi-center , open-label , Phase 3 study L-Dopa responsive PD patient motor fluctuation ( `` OFF '' episode ) , design evaluate long-term safety , tolerability efficacy APL-130277 .</brief_summary>
	<brief_title>An Open-Label Phase 3 Study Examine Long-Term Safety , Tolerability Efficacy APL-130277 Acute Treatment `` OFF '' Episodes Patients With Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Apomorphine</mesh_term>
	<criteria>De Novo Patients : Inclusion Criteria Male female ≥ 18 year age . Clinical diagnosis Idiopathic PD , consistent UK Brain Bank Criteria Clinically meaningful response LDopa determine Investigator . Receiving stable dos LDopa/carbidopa ( immediate chronic release ) administer least 4 time per day OR Rytary™ administer 3 time per day , least 4 week initial Screening Visit ( SV1 ) . No planned medication change ( ) surgical intervention anticipate course study . Patients must experience least one well define `` OFF '' episode per day total daily `` OFF '' time duration ≥ 2 hour wake day , base patient selfassessment . Stage III less modified Hoehn Yahr scale `` ON '' state . MMSE score &gt; 25 . Exclusion Criteria Atypical secondary parkinsonism . Previous treatment follow : neurosurgical procedure PD ; continuous subcutaneous ( s.c. ) apomorphine infusion ; Duodopa/Duopa Treatment form s.c. apomorphine within 7 day prior initial Screening Visit ( SV1 ) . Patients stop s.c. apomorphine reason systemic safety concern lack efficacy may consider . Contraindications APOKYN® , hypersensitivity apomorphine hydrochloride ingredient APOKYN® ( notably sodium metabisulfite ) ; Tigan® ( trimethobenzamide hydrochloride ; patient US site ) ; domperidone ( patient nonUS site ) . Participation clinical trial within 30 day prior initial Screening Visit ( SV1 ) . Currently take selective 5HT3 antagonist ( i.e. , ondansetron , granisetron , dolasetron , palonosetron , alosetron ) , dopamine antagonist ( exclude quetiapine clozapine ) dopamine deplete agent . Drug alcohol dependency past 12 month . History malignant melanoma . Clinically significant medical , surgical , laboratory abnormality opinion Investigator . Major psychiatric disorder include , limited , dementia , bipolar disorder , psychosis , disorder , opinion Investigator , require ongoing treatment would make study participation unsafe make treatment compliance difficult . History clinically significant hallucination past 6 month . History clinically significant impulse control disorder ( ) . Dementia preclude provide informed consent would interfere participation study . Patients Rolling Over CTH300 ( Rollover Patients ) : Inclusion Criteria Completion CTH300 study , opinion Investigator , would benefit continued treatment APL130277 . No treatment form apomorphine ( include APL130277 ) ≥ 2 week follow completion participation CTH300 . No concomitant medication change ( exclude apomorphine ) since completion participation CTH300 plan medication change ( ) surgical intervention anticipate course study . MMSE score &gt; 25 . Exclusion Criteria Receipt investigational ( i.e. , unapproved ) medication participation clinical trial since participate CTH300 . Clinically significant medical , surgical , laboratory abnormality , opinion Investigator . Major psychiatric disorder include , limited , dementia , bipolar disorder , psychosis , disorder , opinion Investigator , require ongoing treatment would make study participation unsafe make treatment compliance difficult . History clinically significant hallucination past 6 month . History clinically significant impulse control disorder ( ) . Dementia preclude provide informed consent would interfere participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>